Table 3 Predictive accuracy based on CV2 scheme for five traits evaluated in WW and WS trials using additive (A) and additive + dominance (AD) models [1]
Model | Trial | GY | EPP | ASI | FFT | MFT |
|---|---|---|---|---|---|---|
WS | ||||||
A | WSJ10 | 0.31 (0.04) | 0.26 (0.04) | 0.70 (0.01) | 0.71 (0.02) | 0.65 (0.03) |
WSJ11 | 0.18 (0.07) | 0.28 (0.05) | 0.47 (0.04) | 0.62 (0.04) | 0.64 (0.03) | |
WST10 | 0.37 (0.02) | 0.61 (0.01) | 0.12 (0.02) | 0.17 (0.05) | 0.40 (0.04) | |
WST11 | 0.29 (0.06) | 0.39 (0.03) | 0.39 (0.02) | 0.40 (0.06) | 0.46 (0.06) | |
AD | WSJ10 | 0.38 (0.03) | 0.27 (0.02) | 0.70 (0.01) | 0.73 (0.02) | 0.59 (0.02) |
WSJ11 | 0.54 (0.02) | 0.48 (0.03) | 0.55 (0.02) | 0.70 (0.02) | 0.57 (0.04) | |
WST10 | 0.34 (0.04) | 0.60 (0.01) | 0.13 (0.02) | 0.16 (0.02) | 0.16 (0.02) | |
WST11 | 0.56 (0.02) | 0.47 (0.01) | 0.41 (0.02) | 0.51 (0.02) | 0.46 (0.05) | |
WW | ||||||
A | WWJ10 | 0.42 (0.03) | 0.42 (0.03) | 0.54 (0.02) | 0.65 (0.03) | 0.62 (0.03) |
WWJ11 | 0.37 (0.03) | 0.44 (0.01) | 0.64 (0.01) | 0.50 (0.03) | 0.55 (0.04) | |
WWT10 | 0.46 (0.02) | 0.55 (0.01) | 0.55 (0.01) | 0.70 (0.01) | 0.62 (0.01) | |
WWT11 | 0.30 (0.02) | 0.38 (0.02) | 0.49 (0.02) | 0.57 (0.02) | 0.57 (0.04) | |
AD | WWJ10 | 0.52 (0.02) | 0.41 (0.02) | 0.55 (0.01) | 0.66 (0.01) | 0.67 (0.01) |
WWJ11 | 0.40 (0.02) | 0.42 (0.02) | 0.62 (0.02) | 0.51 (0.04) | 0.56 (0.02) | |
WWT10 | 0.53 (0.02) | 0.57 (0.01) | 0.54 (0.01) | 0.71 (0.01) | 0.62 (0.02) | |
WWT11 | 0.32 (0.03) | 0.37 (0.03) | 0.48 (0.02) | 0.63 (0.02) | 0.61 (0.01) | |
